Pain after breast cancer surgery may be associated with underlying depression
the ONA take:
Depression may increase the intensity of postoperative acute pain in women with breast cancer, according to a new study published online ahead of print in the journal Psycho-Oncology.
For the study, researchers sought to determine the prevalence of severe, definite depression symptoms among patients with breast cancer and to assess the association between severe depression symptoms and sociodemographic and perioperative factors during the perioperative period.
Researchers analyzed data from 1,499 women with breast cancer who were admitted for definitive breast surgery. Results showed that 2 or more family members with cancer, having a prescription for sedative medication, and persistent, severe pain during the postoperative period were significantly associated with severe, definite depression symptoms.
The findings suggest that self-reporting of persistent postoperative pain intensity among patients with breast cancer may be useful in identifying hidden depression symptoms during the perioperative period.
Depression may increase the intensity of postoperative acute pain in women with breast cancer.
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer
- Clinical Trials May Benefit Oncology Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Immune Thrombocytopenia (Fact Sheet)
- Novel 3D Marker Reduces Radiation, Improves Cosmesis in Breast Conserving Surgery
- Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics
- Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location
- Long-Term Use of TPO Receptor Agonist Safe in CLL-Associated Immune Thrombocytopenia
- Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|